A recent phase 3b clinical trial has revealed promising results in the fight against recurrent Clostridioides difficile infection (rCDI). Specifically, the study showed that Rebyota Fecal Microbiota, live-jslm (RBL), administered through colonoscopy, is a safe and efficacious preventative measure for those susceptible to recurrent bouts of the infection. The trial serves as a benchmark for the healthcare community as hospitals intensify their efforts against this persistent challenge.
Known as the CDI-SCOPE study, this research project involved 41 adults from across 12 different US sites. Participants included those with a history of rCDI who had already finished their routine antibiotic therapy. Each participant was administered a single 150-mL dose of RBL during a colonoscopy procedure. This was applied to the right side of their colon. In the eight weeks that followed, the development of treatment-emergent adverse events (TEAEs) was closely monitored.
Associated TEAEs were reported for a small percentage of individuals who participated in the trial (9.8%), all of which were deemed mild. The success of the treatment was defined by the absence of any recurrence of the CDI infection for a period of two months following administration; it was observed in 95.1% of participants. Furthermore, the study noted positive experiences reported by 90.2% of investigative medical personnel involved in the Rebyota administration and deemed the patient benefit as ‘much improved’ or ‘very much improved’.
The results of this trial drive positive sentiment about Rebyota’s potential to provide a safer and more effective method to prevent recurrent C difficile as compared to older, traditional fecal microbiota transplantation (FMT) methods. The latter approach, considered rudimentary by contemporary standards, involved a donor onsite providing a manually blenderized fecal sample mixed with a saline solution. The Rebyota method introduced a more sophisticated procedure using a pre-prepared, broad consortium of microorganisms administered via colonoscopy, which provides an off-label usage to traditional FMT.
The patients enrolled for this open-label study averaged an age of 61.2 years, were predominantly women (88%) and White (95%). It was observed that 43.9% fell under the category of first recurrence. Physician satisfaction remained high throughout, with 90.2% of the doctors expressing a positive or very positive response about the entire process. It is important to note that the methods of introducing the material differed per site. Regrettably, two participants (4.9%) opted out before the conclusion of the study and had an indeterminate outcome.
However, the high success rates, coupled with supportive physician feedback, brings optimism in the ever-evolving fight against recurrent C difficile. This study’s findings have the potential to lay the groundwork for wider adoption of Rebyota administered via colonoscopy as a standard preventative measure against CDI recurrence. This represents a significant step towards improving patient outcomes and breaking the cycle of C. difficile recurrence.